ArticleRespiratory research2026
Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: an international survey.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConnective tissue diseases (CTDs) and rheumatoid arthritis (RA) share the pulmonary complication of interstitial lung disease (ILD). However, real-world data on patient perspectives and experience regarding screening and evaluations for ILD following CTD/RA diagnosis are limited. We conducted an international, cross-sectional online survey of patients self-reporting as having confirmed CTDs and RA to understand their experience of lung manifestations and ILD screening and/or evaluations.
methodsRespondents aged ≥18 years with self-reported CTDs/RA with and without ILD were engaged across Africa and Turkey, Europe, Japan and the Americas.
resultsOf 2,225 respondents, 54% were from Europe and 82% were female. Mean ± standard deviation (SD) age was 55 ± 11.6 years. Mean (SD) time from first symptoms to diagnosis with CTD/RA was 14.78 ± 11.37 years. On average, respondents experienced a delay of about 2 years before they were diagnosed with CTD/RA after experiencing their first symptoms. Mean (SD) time from CTD/RA diagnosis to diagnosis with lung conditions was 9.61 ± 10.09 years. Lung screening/evaluations were reported to have been done by 70% of all respondents, mostly as a general or routine status check (39%). Chest high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) were the most recalled tests to evaluate the lungs for ILD (both 50%), especially among respondents with systemic sclerosis (73% and 87%, respectively). Among respondents who recalled lung evaluation by chest HRCT scan or PFTs, tests were carried out every 1-2 years. Most survey respondents (87%) rated lung screening/evaluations as important.
conclusionsThe survey demonstrated mixed experiences of evaluations for lung manifestations and ILD among patients with CTDs/RA, attributable to differences in the risk of developing ILD and limited clinical guidance for evaluating for ILD in CTDs/RA. Despite their mixed experiences, most respondents showed a positive attitude towards lung evaluations, which could be leveraged to ensure regular, proactive screening and evaluation for ILD to improve patient outcomes. Overall, findings from this survey highlight opportunities to improve physician awareness and standardisation of practice for enhanced patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.